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Suppression of endothelial nuclear 
factor-κB reduces hypertensive 
renal disease
It is currently thought that hypertension damages the vasculature 
by ﬁrst damaging endothelial cells, where it induces expression of 
adhesion molecules and chemokines. These eﬀects promote inﬂam-
mation and contribute to the pathogenesis of hypertensive vascular 
disease. The hormone angiotensin II (Ang II) activates nuclear fac-
tor-κB (NF-κB), a major transcription factor mediating inﬂam-
mation and innate immunity. Exposure to stimuli such as tumor 
necrosis factor-α (TNF-α), interleukin-1, reactive oxygen species, 
Ang II, and others results in rapid phosphorylation, site-speciﬁc 
ubiquitination, and degradation of the IκB proteins by the protea-
some. The free NF-κB molecules then translocate to the nucleus 
and regulate target expression of several genes, including genes 
involved in the control of cell proliferation, apoptosis, and immune 
response. Thus, NF-κB plays an important role in the development 
of hypertensive organ damage, but its location in the vessel wall that 
participates in hypertensive disease is unclear.
To address this question, Henke et al. used the Cre/lox technique 
to generate transgenic mice with endothelial cell-restricted NF-κB 
super-repressor IκBα∆N overexpression (Tie-1-∆N mice). In pri-
mary endothelial-cell cultures, they found IκBα∆N expression and 
reduced NF-κB activity after TNF-α stimulation. To induce hyper-
tension with vascular damage, they fed mice a high-salt diet and 
N(ω)-nitro-l-arginine-methyl-ester (l-NAME) and infused them 
with Ang II. This treatment caused an increase in blood pressure (to 
40 mm Hg) in both Tie-1-∆N and control mice. However, in con-
trast to control mice, Tie-1-∆N mice developed milder renal injury, 
reduced inﬂammation, and less albuminuria. RT-PCR signiﬁcantly 
reduced expression of the NF-κB targets VCAM-1 and ICAM-1, 
compared with that in control mice (Figure). Thus, this study dem-
onstrates a causal link between endothelial NF-κB activation and 
hypertension-induced renal damage. In vivo NF-κB suppression 
in endothelial cells may provide a therapeutic approach to reduce 
hypertension-induced renal disease despite high blood pressure. 
(Circ Res 2007; 101: 268–276)
Juan Oliver
Toxin from sea anemone causes 
glomerular endothelial damage
Sea anemones are armed with venom-secreting nematocysts to 
capture prey and protect themselves from predators. Most of these 
venoms are harmless to humans or induce mild dermatitis, but a 
few species of sea anemones possess highly toxic venoms. Phyllo-
discus semoni is one of the most dangerous; it is commonly called 
the ‘night sea anemone’ and is distributed in the Western Paciﬁc 
ocean. The sting induces severe dermatitis with local ulceration 
and swelling that often takes months to resolve and may lead to 
acute renal failure. However, the incidence of this complication 
is unknown. Several hemolytic protein toxins have been isolated 
from P. semoni venom, including a 20-kilodalton and a 60-kilodal-
ton protein. Renal injury has been reported following envenoma-
tion by snakes, spiders, and scorpions. In some instances, these 
eﬀects are associated with complement-activating components in 
the venoms that indirectly contribute to tissue damage.
Mizuno et al. investigated whether the venom extracted from 
the nematocysts of P. semoni was nephrotoxic and induced activa-
tion of the complement system when administered intravenously 
in rats (Figure). Small doses induced renal pathology similar to 
that seen in patients, with kidneys displaying glomerular injury 
with glomerular endothelial damage, thrombus formation, 
mesangiolysis, and partial rupture of glomerular basement mem-
brane, and severe tubular necrosis. These ﬁndings are similar to 
those of severe hemolytic uremic syndrome. Early-stage injury 
was accompanied by speciﬁc toxin binding, massive comple-
ment C3b, membrane attack complex deposition in glomeruli, 
and decreased glomerular expression of complement regulators. 
Systemic complement inhibition reduced renal injury, conﬁrming 
a pathogenic role for complement. Puriﬁcation and isolation of 
the nephrotoxic fraction showed a 115-kilodalton protein toxin, 
which caused identical renal pathology. Demonstration that the 
highly nephrotoxic toxin induced complement activation suggests 
that inhibition of complement might be used to prevent acute 
renal damage following envenomation by P. semoni. Additional 
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Hypertension-induced kidney damage is diminished in Tie-1-∆N mice. 
Renal fibrosis; Sirius red staining.
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Complement regulator expression after ex vivo exposure of kidney 
sections to the venom extracted from the nematocysts.
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studies on this isolated nephrotoxic protein would be of great 
interest. (Am J Pathol 2007; 171: 402–414)
Juan Oliver
Ace2 protects against diabetic 
kidney injury
Activation of the renin–angiotensin system and generation of 
angiotensin II play important roles in the pathogenesis of diabetic 
nephropathy, and blockade of the system attenuates diabetic kidney 
injury. The recent discovery of angiotensin-converting enzyme-
2 (ACE2) has revealed that processing of angiotensin is more 
complicated than previously thought. Like ACE, ACE2 is mem-
brane-bound, but it is a monocarboxypeptidase that generates angio-
tensin(1–9) from the decapeptide angiotensin I and angiotensin(1–7) 
from angiotensin II. Thus, ACE2 serves the dual function of degrad-
ing the vasoconstrictor angiotensin II and producing the vasodila-
tor angiotensin(1–7). Moreover, angiotensin(1–7) has been reported 
to inhibit angiotensin II-mediated cell signaling and reduce angio-
tensin II expression of transforming growth factor-β1.
In diabetic rodent models, early increases in ACE2 mRNA lev-
els, protein expression, and activity have been reported, whereas 
decreases in ACE2 mRNA and protein levels have been found in 
older streptozotocin-induced diabetic rats. These studies suggest 
that ACE2 may play a protective role in the development of diabetic 
nephropathy. To test this hypothesis, Wong et al. used Akita mice 
(Ins2WT/C96Y), a model of type 1 diabetes mellitus, and mice with 
a deletion of the Ace2 gene (Ace2–/y). The Akita mouse harbors a 
missense mutation of the insulin 2 gene that renders the mouse 
insulin-deﬁcient. The authors crossed Ace2–/– mice with Akita mice 
(Ins2WT/C96Y). Four groups of mice were studied at 3 months of 
age: Ace2+/yIns2WT/WT, Ace2–/yIns2WT/WT, Ace2+/yIns2WT/C96Y, 
and Ace2–/yIns2WT/C96Y. The Ace2+/yIns2WT/C96Y mouse is a 
preferred murine model for the study of diabetic nephropathy 
because it develops sustained hyperglycemia, renal hypertrophy, 
and increased urinary albumin excretion. Ace2–/yIns2WT/C96Y 
mice exhibited a twofold increase in the urinary albumin excre-
tion rate compared with Ace2+/yIns2WT/C96Y mice despite similar 
blood glucose levels. In addition, Ace2–/yIns2WT/C96Y mice were the 
only group to exhibit increased mesangial matrix and glomerular 
basement membrane thicknesses and ﬁbronectin (Figure), and 
α-smooth muscle actin immunostaining in the glomeruli. There 
were no diﬀerences in blood pressure or heart function to account 
for the exacerbation of kidney injury. Although kidney levels of 
angiotensin II did not increase in diabetic mice, treatment with 
an angiotensin II receptor blocker reduced the urinary albumin 
excretion rate in Ace2–/yIns2WT/C96Y mice. This ﬁnding suggests 
that ACE2 has a protective role in the diabetic kidney and is an 
important enzyme in preventing diabetic nephropathy. (Am J Pathol 
2007; 171: 438–451)
Juan Oliver
Treatment of AA amyloidosis renal 
disease
The amyloidoses are a group of diseases in which proteins are depos-
ited extracellularly in tissues as insoluble ﬁbrils, causing progressive 
organ dysfunction and death. Amyloid A (AA) amyloidosis, also 
referred to as secondary amyloidosis, is a rare but serious com-
plication of chronic inﬂammatory diseases and infections. The 
amyloidogenic protein in AA amyloidosis is a proteolytic frag-
ment of serum amyloid A protein (SAA), an acute-phase reactant 
produced by the liver. Deposition of amyloid in the kidney results 
in proteinuria and progressive loss of renal function. Treatments 
that reduce production of the amyloidogenic protein can improve 
organ function and survival in immunoglobulin-light-chain-related 
amyloidosis and hereditary transthyretin-associated amyloidosis.
Several studies suggest that glycosaminoglycans, such as heparan 
sulfate, are critical in the pathogenesis of amyloidosis, and that 
interactions between amyloidogenic proteins and glycosaminogly-
cans promote ﬁbril assembly and stabilize amyloid deposits in 
tissues. Eprodisate is a member of a new class of agents that inter-
fere with interactions between amyloidogenic proteins and gly-
cosaminoglycans, and inhibit development of amyloid deposits 
in the tissues in mouse models of AA amyloidosis. To determine 
whether eprodisate prevents the progression of AA amyloidosis in 
humans, Dember et al. conducted a multicenter, randomized, dou-
ble-blind, placebo-controlled trial in patients with AA amyloido-
sis-associated nephropathy. In all, 183 patients from 27 centers 
were randomly assigned to receive eprodisate or placebo for 24 
months. The primary composite end point was an assessment 
of renal function or death. Disease was classiﬁed as worsened if 
any one of the following occurred: doubling of serum creatinine, 
reduction in creatinine clearance by 50% or more, progression to 
end-stage renal disease, or death. Two years after treatment began, 
disease worsened in 27% of patients who received eprodisate and 
40% of those given placebo (P = 0.06).  The mean rates of decline 
in creatinine clearance were 10.9 and 15.6 ml per minute per 1.73 
m2 of body-surface area per year in the eprodisate and placebo 
groups, respectively (P = 0.02). The drug had no signiﬁcant eﬀect 
on progression to end-stage renal disease or risk of death. The 
incidence of adverse events was similar in the two groups. Thus, 
eprodisate was shown to slow the decline of renal function in AA 
amyloidosis. (N Engl J Med 2007; 356: 2349–2360)
Juan Oliver
Representative light micrographs of fibronectin immunostaining in 
kidney sections from each group of mice.
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